SGLT-2 inhibitors have been shown to reduce albuminuria and the risk of CKD progression, as well as lower mortality and cardiovascular event rates in adults with T2D and CKD [87,88]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.